ALLO-1a is a ubiquitin-binding adaptor for allophagy in Caenorhabditis elegans
Journal of Cell Science · 2024
DOI: 10.1242/jcs.264252 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cell Science, 2024. Verfasst von Takuya Norizuki und 9 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Molecular Membrane Biology, Institute for Molecular and Cellular Regulation, Gunma University, Maebashi, Gunma 371-8512, Japan. Hauptthemen laut MEDLINE: Caenorhabditis elegans, Caenorhabditis elegans Proteins, Ubiquitin, Autophagy. Die Arbeit nennt 46 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science, Core Research for Evolutional Science and Technology, Japan Agency for Medical Research and Development.
Abstract (Originalsprache)
In the nematode Caenorhabditis elegans, sperm-derived mitochondria and membranous organelles (MOs) are selectively degraded by autophagy in embryos in a process termed allophagy. For this process, ALLO-1 functions as an autophagy adaptor. The allo-1 gene encodes two splice isoforms, ALLO-1a and ALLO-1b, which have different C-terminal sequences and are predominantly targeted to MOs and paternal mitochondria, respectively. However, the mechanism by which ALLO-1 targets the paternal organelles remains unknown. In this study, X-ray crystallography analysis reveals that the C-terminal region of ALLO-1a forms a parallel coiled-coil structure. In addition, AlphaFold2-Multimer predicts that this region directly interacts with ubiquitin. We showed that ALLO-1a interacts with K48- and K63-linked polyubiquitin in vitro and found that the D355 residue of ALLO-1a at the predicted interface with ubiquitin is important for its ubiquitin binding in vitro and also for its MO targeting and MO degradation in embryos. These results suggest that ubiquitin is a marker for the recognition of MOs by the autophagy machinery in C. elegans embryos.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Molecular Membrane Biology, Institute for Molecular and Cellular Regulation, Gunma University, Maebashi, Gunma 371-8512, Japan.
- Laboratory of Molecular Traffic, Institute for Molecular and Cellular Regulation, Gunma University, Maebashi, Gunma 371-8512, Japan.
- Department of Biomolecular Pathogenesis, Medical Research Laboratory, Institute of Integrated Research, Institute of Science Tokyo, Bunkyo-ku, Tokyo 113-8510, Japan.
- Intracellular Quality Control Project , Tokyo Metropolitan Institute of Medical Science, Setagaya-ku, Tokyo 156-8506, Japan.
- Institute for Genetic Medicine , Hokkaido University, Sapporo, Hokkaido 060-0815, Japan.
- Institute of Microbial Chemistry, Shinagawa-ku, Tokyo 141-0021, Japan.
ORCID-Profile: Takuya Norizuki, Takayuki Sekimoto, Taeko Sasaki, Koji Yamano, Noriyuki Matsuda, Ryohei Sasaki, Nobuo N Noda, Ken Sato, Miyuki Sato
Förderung
- Japan Society for the Promotion of Science
- Core Research for Evolutional Science and Technology
- Japan Agency for Medical Research and Development
- Takeda Science Foundation
- Ministry of Education, Culture, Sports, Science and Technology
- Japan Science and Technology Agency
Zitieren
APA
Norizuki, T., Kushida, Y., Sekimoto, T., Sasaki, T., Yamano, K., Matsuda, N., Sasaki, R., Noda, N. N., Sato, K., & Sato, M. (2024). ALLO-1a is a ubiquitin-binding adaptor for allophagy in Caenorhabditis elegans. Journal of Cell Science. https://doi.org/10.1242/jcs.264252
Vancouver
Norizuki T, Kushida Y, Sekimoto T, Sasaki T, Yamano K, Matsuda N, et al. ALLO-1a is a ubiquitin-binding adaptor for allophagy in Caenorhabditis elegans. Journal of Cell Science. 2024. doi:10.1242/jcs.264252
BibTeX
@article{Norizuki2024,
author = {Norizuki, Takuya and Kushida, Yasuharu and Sekimoto, Takayuki and Sasaki, Taeko and Yamano, Koji and Matsuda, Noriyuki and Sasaki, Ryohei and Noda, Nobuo N and Sato, Ken and Sato, Miyuki},
title = {ALLO-1a is a ubiquitin-binding adaptor for allophagy in Caenorhabditis elegans},
journal = {Journal of Cell Science},
year = {2024},
doi = {10.1242/jcs.264252}
}
EUVIMED